Cargando…
Valganciclovir as Add-On Therapy Modifies the Frequency of NK and NKT Cell Subpopulations in Disseminated Kaposi Sarcoma Patients
SIMPLE SUMMARY: Kaposi sarcoma is one disease that develops in people living with HIV with severe immunosuppression and impacts morbidity and associated mortality. This disease is currently treated with antiretroviral therapy and chemotherapy agents that can further contribute to immunosuppression i...
Autores principales: | Flores-Gonzalez, Julio, Ramon-Luing, Lucero A., Ocaña-Guzman, Ranferi, Buendia-Roldan, Ivette, Islas-Muñoz, Beda, Volkow-Fernández, Patricia, Chavez-Galan, Leslie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773484/ https://www.ncbi.nlm.nih.gov/pubmed/35053573 http://dx.doi.org/10.3390/cancers14020412 |
Ejemplares similares
-
Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial
por: Volkow, Patricia, et al.
Publicado: (2023) -
Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
por: Stragliotto, Giuseppe, et al.
Publicado: (2020) -
CD4+T cells in ageing-associated interstitial lung abnormalities show evidence of pro-inflammatory phenotypic and functional profile
por: Machahua, Carlos, et al.
Publicado: (2021) -
Murine RAW Macrophages Are a Suitable Model to Study the CD3 Signaling in Myeloid Cells
por: Ocaña-Guzmán, Ranferi, et al.
Publicado: (2022) -
Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma
por: Pantalone, Mattia Russel, et al.
Publicado: (2022)